Aging biology has a strange villain: cells that stop dividing but refuse to die. These are called senescent cells — sometimes nicknamed “zombie cells” — and they accumulate steadily in tissues throughout the body as you age.
Under normal conditions, senescent cells play a short-term role: they send out chemical signals that recruit the immune system to remove them. But when that clearance fails — as it increasingly does with age — they persist. And they leak. The toxic cocktail they continuously secrete is called the senescence-associated secretory phenotype, or SASP: a mix of inflammatory proteins, enzymes, and growth factors that damage surrounding tissue, promote chronic inflammation, and accelerate the aging of neighboring healthy cells.
As few as 1 to 2 senescent cells per 100 total cells are now thought to drive a disproportionate share of age-related physical decline, according to researchers. In 2015, researchers at the Mayo Clinic demonstrated this directly: clearing just 30 to 50 percent of senescent cells in aging mice significantly extended healthy lifespan, with the mice staying more physically active and experiencing far lower rates of age-related disease.
The field that grew from that finding is called senolytics — and as of 2026, it has moved firmly into human clinical trials.
What Senolytics Are and How They Work
Senolytic compounds work by targeting the specific survival pathways that protect senescent cells from their own internal death signals. Normal cells that become damaged typically activate apoptosis — programmed cell death — and eliminate themselves. Senescent cells resist this process by upregulating anti-apoptotic proteins. Senolytics temporarily disable those pro-survival defenses, allowing the senescent cells to finally die while leaving healthy cells unaffected.
The most studied senolytic combination is dasatinib plus quercetin (D+Q). Dasatinib is an FDA-approved cancer drug; quercetin is a natural flavonoid found in apples, onions, and capers. Used intermittently rather than continuously — the drugs are taken in short “hit-and-run” cycles — they have shown the ability to reduce senescent cell burden in human tissue.
A pivotal Mayo Clinic trial was the first to directly demonstrate that senolytics decrease senescent cells in living humans: a 3-day oral course of D+Q in patients with diabetic kidney disease reduced adipose tissue senescent cell burden within 11 days, with measurable decreases in key senescence markers (p16INK4A, p21CIP1) and circulating inflammatory factors including IL-1α, IL-6, and MMP-9 and MMP-12. That was a proof-of-concept result — small scale, short duration — but it was the first human evidence that the drugs actually do what they are supposed to do at the cellular level.
Where the Trials Stand in 2026
As of 2026, more than 80 human clinical trials are investigating senolytic compounds across a range of age-related conditions. Three areas have produced the most substantive early results:
Alzheimer’s Disease. Two open-label Phase 1 trials — SToMP-AD and STAMINA — have evaluated 12 weeks of intermittent D+Q in older adults with or at risk for Alzheimer’s disease. The STAMINA trial found that reductions in plasma TNF-α (a key inflammatory marker) significantly correlated with improvements in cognitive test scores (MoCA), with a correlation coefficient of −0.65, p=0.02. Both trials supported the safety and biological activity of senolytic therapy in this population. A Phase 2 randomized controlled trial of D+Q for Alzheimer’s is now underway.
Chronic Kidney Disease. A completed Phase 2 trial of D+Q at Mayo Clinic showed improved kidney function scores and reduced inflammatory markers in 20 patients over 6 months — described as “the first human evidence of functional improvement from senolytic clearance in a chronic disease setting.”
Frailty and Physical Function. Earlier work in patients with idiopathic pulmonary fibrosis (IPF) — a fatal senescence-associated lung disease — produced the first clinical signal that senolytics could improve physical function in humans. Short-term, intermittent administration of D+Q produced clinically meaningful improvements in mobility in IPF patients, supporting progression to larger randomized trials.
What the Evidence Does and Does Not Show
It is important to be precise about what these trials have established. They have shown that:
- Senolytic drugs can measurably reduce senescent cell burden in human tissue
- The reduction in senescent cells correlates with decreases in inflammatory markers
- Some functional improvements — in kidney function, mobility, and early cognitive measures — have appeared in small trials
What they have not shown:
- That senolytics extend human lifespan
- That clearing senescent cells reverses aging systemically
- That the improvements hold in large, randomized, placebo-controlled trials (most results to date are from open-label or small Phase 1/2 designs)
- That intermittent use over years is safe — long-term safety data is still accumulating
As researchers noted in a 2026 overview of the field, the field is still building toward “validated surrogate endpoints” — and the FDA’s guidance for geroscience trials encourages functional measures like walking speed and fall rates, not biomarker changes alone. None of the current trials use lifespan as a primary endpoint because that would require decades of follow-up.
What Is Available Now — and What to Be Cautious About
Dasatinib requires a prescription and carries real risks — it is a cancer drug with an established side effect profile. Quercetin is available as a supplement. Fisetin (found naturally in strawberries) and other natural compounds are also being studied as senolytics.
The interest in self-administered “DIY senolytics” is significant in the longevity community. The honest assessment: the clinical trial evidence supports senolytic biology in humans, but it does not yet support self-directed use outside a monitored clinical setting. The intermittent dosing protocols used in trials were designed with safety monitoring precisely because the drugs do have real pharmacological effects.
If you are interested in senolytic clinical trial participation, ClinicalTrials.gov lists current enrolling studies across conditions from Alzheimer’s to osteoarthritis to frailty.
